ATE487480T1 - Perhexilin zur behandlung von chronischer herzinsuffizienz - Google Patents
Perhexilin zur behandlung von chronischer herzinsuffizienzInfo
- Publication number
- ATE487480T1 ATE487480T1 AT04768382T AT04768382T ATE487480T1 AT E487480 T1 ATE487480 T1 AT E487480T1 AT 04768382 T AT04768382 T AT 04768382T AT 04768382 T AT04768382 T AT 04768382T AT E487480 T1 ATE487480 T1 AT E487480T1
- Authority
- AT
- Austria
- Prior art keywords
- heart failure
- chronic heart
- perhexiline
- treatment
- ischaemic
- Prior art date
Links
- 206010007558 Cardiac failure chronic Diseases 0.000 title abstract 7
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000989 perhexiline Drugs 0.000 title abstract 3
- 230000000302 ischemic effect Effects 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- External Artificial Organs (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0405381.5A GB0405381D0 (en) | 2004-03-10 | 2004-03-10 | A method and means for treating heart failure |
| PCT/GB2004/003835 WO2005087233A1 (en) | 2004-03-10 | 2004-09-07 | Perhexilin for treating chronic heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE487480T1 true ATE487480T1 (de) | 2010-11-15 |
Family
ID=32117402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04768382T ATE487480T1 (de) | 2004-03-10 | 2004-09-07 | Perhexilin zur behandlung von chronischer herzinsuffizienz |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20070275997A1 (de) |
| EP (1) | EP1732551B1 (de) |
| JP (1) | JP5087389B2 (de) |
| CN (1) | CN1950084A (de) |
| AT (1) | ATE487480T1 (de) |
| DE (1) | DE602004030048D1 (de) |
| DK (1) | DK1732551T3 (de) |
| ES (1) | ES2358514T3 (de) |
| GB (1) | GB0405381D0 (de) |
| MX (1) | MXPA06010397A (de) |
| PL (1) | PL1732551T3 (de) |
| PT (1) | PT1732551E (de) |
| WO (1) | WO2005087233A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0405381D0 (en) | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
| GB0723100D0 (en) * | 2007-11-23 | 2008-01-02 | Heart Metabolics Ltd | Treatment of HFnEF |
| GB0908193D0 (en) * | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
| AU2009346606B2 (en) * | 2009-05-20 | 2016-06-02 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
| US9393221B2 (en) | 2011-07-20 | 2016-07-19 | The General Hospital Corporation | Methods and compounds for reducing intracellular lipid storage |
| US20140065241A1 (en) * | 2012-09-05 | 2014-03-06 | Adelaide Research & Innovation Pty Ltd | Uses of (-)-perhexiline |
| CN102988347A (zh) * | 2012-11-19 | 2013-03-27 | 何晓涛 | Aphanamixoid A在制备治疗或预防慢性心衰的药物中的应用 |
| GB201308736D0 (en) * | 2013-05-15 | 2013-06-26 | Univ Aberdeen | Compounds and their therapeutic use |
| JP2015147787A (ja) * | 2015-04-01 | 2015-08-20 | ハート メタボリクス リミテッド | 正常駆出率心不全の治療 |
| WO2021127003A1 (en) * | 2019-12-16 | 2021-06-24 | Children's Medical Center Corporation | Treating heart disease in muscular dystrophy patients |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN380695A0 (en) * | 1995-06-23 | 1995-07-20 | Queen Elizabeth Hospital, The | Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions |
| US20030162824A1 (en) * | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
| CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
| GB0405381D0 (en) | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
| CA2560416A1 (en) | 2004-04-06 | 2005-10-20 | Angiogenetics Sweden Ab | Angiogenesis-affecting compounds and methods of use thereof |
| GB0723100D0 (en) | 2007-11-23 | 2008-01-02 | Heart Metabolics Ltd | Treatment of HFnEF |
| GB0908193D0 (en) | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
| AU2009346606B2 (en) | 2009-05-20 | 2016-06-02 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
-
2004
- 2004-03-10 GB GBGB0405381.5A patent/GB0405381D0/en not_active Ceased
- 2004-09-07 DE DE602004030048T patent/DE602004030048D1/de not_active Expired - Lifetime
- 2004-09-07 PL PL04768382T patent/PL1732551T3/pl unknown
- 2004-09-07 JP JP2007502376A patent/JP5087389B2/ja not_active Expired - Fee Related
- 2004-09-07 US US10/592,250 patent/US20070275997A1/en not_active Abandoned
- 2004-09-07 PT PT04768382T patent/PT1732551E/pt unknown
- 2004-09-07 DK DK04768382.6T patent/DK1732551T3/da active
- 2004-09-07 CN CNA2004800429346A patent/CN1950084A/zh active Pending
- 2004-09-07 WO PCT/GB2004/003835 patent/WO2005087233A1/en not_active Ceased
- 2004-09-07 AT AT04768382T patent/ATE487480T1/de active
- 2004-09-07 EP EP04768382A patent/EP1732551B1/de not_active Expired - Lifetime
- 2004-09-07 ES ES04768382T patent/ES2358514T3/es not_active Expired - Lifetime
- 2004-09-07 MX MXPA06010397A patent/MXPA06010397A/es active IP Right Grant
-
2011
- 2011-09-23 US US13/244,103 patent/US8470806B2/en not_active Expired - Fee Related
-
2013
- 2013-03-15 US US13/841,465 patent/US8697677B2/en not_active Expired - Fee Related
- 2013-03-15 US US13/841,635 patent/US20130331321A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130224118A1 (en) | 2013-08-29 |
| EP1732551B1 (de) | 2010-11-10 |
| WO2005087233A1 (en) | 2005-09-22 |
| EP1732551A1 (de) | 2006-12-20 |
| MXPA06010397A (es) | 2007-04-23 |
| US8697677B2 (en) | 2014-04-15 |
| US20130331321A1 (en) | 2013-12-12 |
| US8470806B2 (en) | 2013-06-25 |
| ES2358514T3 (es) | 2011-05-11 |
| JP2007528378A (ja) | 2007-10-11 |
| PT1732551E (pt) | 2011-02-15 |
| US20070275997A1 (en) | 2007-11-29 |
| GB0405381D0 (en) | 2004-04-21 |
| PL1732551T3 (pl) | 2011-05-31 |
| JP5087389B2 (ja) | 2012-12-05 |
| CN1950084A (zh) | 2007-04-18 |
| US20120101128A1 (en) | 2012-04-26 |
| DK1732551T3 (da) | 2011-02-28 |
| DE602004030048D1 (de) | 2010-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| EA200802412A1 (ru) | Терапевтические комбинации для сопровождающихся болью медицинских состояний | |
| IL192100A0 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | |
| EA201070740A1 (ru) | Способ лечения перелома кости антителами против склеростина | |
| EA201301078A1 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| ATE506059T1 (de) | Therapie zur behandlung der überaktiven blase | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
| ATE457729T1 (de) | Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie | |
| SE0400184D0 (sv) | New therapeutical use | |
| ATE543492T1 (de) | Behandlung von lungenkrebs | |
| EA201300421A1 (ru) | Комбинированная терапия для лечения инфекции hcv | |
| ATE525084T1 (de) | Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| EA200970345A1 (ru) | Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина | |
| ATE414522T1 (de) | Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure | |
| ATE487480T1 (de) | Perhexilin zur behandlung von chronischer herzinsuffizienz | |
| EA200700407A1 (ru) | Производные хиназолина и их использования при лечении тромбоцитемии | |
| EA200600284A1 (ru) | Дооперационное лечение послеоперационной боли | |
| MX2008002456A (es) | Uso de ambroxol para el tratamiento de infecciones por rinovirus. | |
| MX2009006670A (es) | Composicion farmaceutica que usa el aliskiren y el avosentan. | |
| ATE298240T1 (de) | Getrennte dosis therapien mit gefässschädigender aktivität | |
| EA200600989A1 (ru) | Применение габоксадола для лечения бессонницы | |
| DE602006020838D1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1732551 Country of ref document: EP |